Compare Gigacloud Technology Inc (GCT) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gigacloud Technology Inc vs ResMed Inc. — how do they compare? Gigacloud Technology Inc trades at $56.1 (market cap $2.02B), while ResMed Inc. trades at $228.37 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 15.8× Gigacloud Technology Inc's market cap, and ResMed Inc. pays a 1.16% dividend while Gigacloud Technology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gigacloud Technology Inc for 21 Days and ResMed Inc. for 51 Days on average.
| GCT | RMD | |
|---|---|---|
Market Cap | $2.02B | $31.89B |
Volume | 1,020,985 | 618,314 |
Sector | Technology | Health |
52-Week High | $56.42 | $277.88 |
52-Week Low | $25.46 | $182.82 |
Typical Hold Time | 21 Days | 51 Days |
Enterprise Value | $2.14B | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GCT trades at $55.96, up 2.19% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with consistent earnings beats, 10.65% net margins, and 27.6% YoY revenue growth in Q2 2026. Recent news highlights institutional interest and European expansion driving optimism.
The outlook remains positive with 66.7% analyst buy ratings and a $32.50 consensus target, though RSI levels suggest potential near-term consolidation. Key risks include insider selling activity and market volatility, but strong cash flow generation and disciplined expansion support long-term growth prospects.
ResMed (RMD) trades at $228.37, up 1.06% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%. Recent news highlights management's presentation at the Morgan Stanley Healthcare Conference and an upcoming Q1 2027 earnings report.
The outlook is positive, supported by earnings growth targets of 12-14% and a consensus price target of $242.70. Key risks include competitive pressures and ongoing legal investigations. Institutional buying activity and analyst upgrades reflect confidence, but investors should monitor execution against growth targets and any developments from the legal probe.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gigacloud Technology Inc
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
